Stocks and Investing
Stocks and Investing
Wed, November 20, 2019
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Tue, November 19, 2019
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Mon, November 18, 2019
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Joel Beatty Maintained (SRPT) at Strong Buy with Decreased Target to $167 on, Nov 18th, 2019
Joel Beatty of Citigroup, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Strong Buy with Decreased Target from $180 to $167 on, Nov 18th, 2019.
Joel has made no other calls on SRPT in the last 4 months.
There are 5 other peers that have a rating on SRPT. Out of the 5 peers that are also analyzing SRPT, 0 agree with Joel's Rating of Hold.
These are the ratings of the 5 analyists that currently disagree with Joel
- Alethia Young of "Credit Suisse" Maintained at Buy with Decreased Target to $185 on, Friday, November 8th, 2019
- Whitney Ijem of "Guggenheim" Initiated at Strong Buy and Held Target at $183 on, Friday, November 1st, 2019
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $160 on, Friday, October 11th, 2019
- Yun Zhong of "Janney Montgomery Scott" Maintained at Strong Buy with Decreased Target to $175 on, Tuesday, August 20th, 2019
- Brian Skorney of "Baird" Maintained at Buy with Decreased Target to $181 on, Tuesday, August 20th, 2019